Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 191 articles:
HTML format
Text format



Single Articles


    January 2020
  1. CRAIG S, Viros A
    New biomarkers improve stratification of patients with melanoma.
    Br J Dermatol. 2020;182:5-6.
    PubMed     Text format    


    December 2019
  2. THOMPSON JF, Friedman EB
    The intriguing association between smoking and reduced melanoma risk.
    Br J Dermatol. 2019 Dec 23. doi: 10.1111/bjd.18728.
    PubMed     Text format    


  3. DOCAMPO-SIMON A, Sanchez-Pujol MJ, Belinchon-Romero I, Niveiro M, et al
    Image Gallery: Haematogenous metastasis of melanoma mimicking lymphangioma.
    Br J Dermatol. 2019 Dec 17. doi: 10.1111/bjd.18723.
    PubMed     Text format    


  4. BETZ-STABLEIN B, Koh U, Plasmeijer E, Janda M, et al
    Self-reported naevus density may lead to misclassification of melanoma risk.
    Br J Dermatol. 2019 Dec 12. doi: 10.1111/bjd.18802.
    PubMed     Text format     Abstract available


  5. MCMENIMAN EK, Duffy DL, Jagirdar K, Lee KJ, et al
    The interplay of sun-damage and genetic risk in Australian multiple and single primary melanoma cases and controls.
    Br J Dermatol. 2019 Dec 3. doi: 10.1111/bjd.18777.
    PubMed     Text format     Abstract available


    November 2019
  6. BELL KJL
    Causal inference in melanoma epidemiology using Mendelian randomization.
    Br J Dermatol. 2019 Nov 28. doi: 10.1111/bjd.18646.
    PubMed     Text format    


  7. ROBINSON JK
    Frequency of 'regular' skin checks by dermatologists for melanoma survivors.
    Br J Dermatol. 2019 Nov 27. doi: 10.1111/bjd.18626.
    PubMed     Text format    


  8. WEBER J, Glutsch V, Geissinger E, Haug L, et al
    Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In-transit Disease.
    Br J Dermatol. 2019 Nov 26. doi: 10.1111/bjd.18739.
    PubMed     Text format     Abstract available


  9. OLSEN CM, Pandeya N, Law MH, MacGregor S, et al
    Does polygenic risk influence associations between sun exposure and melanoma?: a prospective cohort analysis.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18703.
    PubMed     Text format     Abstract available


  10. LAN J, Wen J, Cao S, Yin T, et al
    The diagnostic accuracy of dermoscopy and reflectance confocal microscopy for amelanotic/hypomelanotic melanoma: a systematic review and meta-analysis.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18722.
    PubMed     Text format     Abstract available


  11. FUJIMURA T, Tanita K, Sato Y, Lyu C, et al
    Immune checkpoint inhibitor-induced vitiligo in advanced melanoma could be related to increased levels of CCL19.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18721.
    PubMed     Text format     Abstract available


  12. JOHANSSON P
    Differences between acral and nonacral melanoma genomes.
    Br J Dermatol. 2019 Nov 19. doi: 10.1111/bjd.18615.
    PubMed     Text format    


  13. DEL REGNO L, Louveau B, Battistella M, Sadoux A, et al
    Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort.
    Br J Dermatol. 2019 Nov 1. doi: 10.1111/bjd.18641.
    PubMed     Text format     Abstract available


  14. DUFFY DL, Lee KJ, Jagirdar K, Pflugfelder A, et al
    Naevus count and MC1R R alleles contribute to melanoma risk.
    Br J Dermatol. 2019;181:e119-e142.
    PubMed     Text format     Abstract available


    October 2019
  15. AGUILAR JA, Irurzun AL, Bayona JIY, Rodriguez MA, et al
    Image Gallery: Zosteriform metastasis from melanoma.
    Br J Dermatol. 2019 Oct 30. doi: 10.1111/bjd.18567.
    PubMed     Text format    


  16. HOWARD M, Xie C, Wee E, Wolfe R, et al
    Acral lentiginous melanoma: differences in survival compared to other subtypes.
    Br J Dermatol. 2019 Oct 19. doi: 10.1111/bjd.18620.
    PubMed     Text format     Abstract available


  17. TOLAND AE
    Developing risk prediction models for melanoma: balancing better predictive value with ease of clinical implementation.
    Br J Dermatol. 2019 Oct 13. doi: 10.1111/bjd.18531.
    PubMed     Text format    


  18. DEINLEIN T, Longo C, Schulter G, Pizzichetta MA, et al
    The prevailing dermoscopic vascular pattern in melanoma is influenced by tumor thickness and pigmentation type.
    Br J Dermatol. 2019 Oct 12. doi: 10.1111/bjd.18610.
    PubMed     Text format     Abstract available


    September 2019
  19. CLAESON M, Baade P, Brown S, Soyer HP, et al
    Clinicopathological factors associated with death from thin (</=1.00mm) melanoma.
    Br J Dermatol. 2019 Sep 28. doi: 10.1111/bjd.18560.
    PubMed     Text format     Abstract available


  20. KOSTAKI M, Plaka M, Stergiopoulou A, Kypreou K, et al
    Trends in epidemiology of melanoma in situ in Greece: Data from a melanoma reference center during the period 2000-2018.
    Br J Dermatol. 2019 Sep 23. doi: 10.1111/bjd.18551.
    PubMed     Text format     Abstract available


  21. GIBSON JAG, Dobbs TD, Griffiths R, Song J, et al
    The Association of Smoking and Socioeconomic status on Cutaneous Melanoma: a population based, data linkage, case-control study.
    Br J Dermatol. 2019 Sep 17. doi: 10.1111/bjd.18526.
    PubMed     Text format     Abstract available


  22. CUST AE, Badcock C, Smith J, Thomas NE, et al
    A risk prediction model for development of subsequent primary melanoma in a population-based cohort.
    Br J Dermatol. 2019 Sep 14. doi: 10.1111/bjd.18524.
    PubMed     Text format     Abstract available


  23. BAILEY EE, Mayer JE, Geller AC, Johnson TM, et al
    Role of the partner/spouse in melanoma discovery and related health behaviors and practices.
    Br J Dermatol. 2019 Sep 5. doi: 10.1111/bjd.18478.
    PubMed     Text format     Abstract available


  24. STILLER HT, Mikiver R, Uppugunduri S, Lindholm C, et al
    Health Related Quality of Life in Melanoma Patients - characterization of a Swedish cohort.
    Br J Dermatol. 2019 Sep 5. doi: 10.1111/bjd.18486.
    PubMed     Text format     Abstract available


    August 2019
  25. GOLDINGER SM, Valeska Matter A, Urner-Bloch U, Narainsing J, et al
    Binimetinib in heavily pretreated NRAS-mutant Melanoma Patients with Brain Metastases.
    Br J Dermatol. 2019 Aug 22. doi: 10.1111/bjd.18449.
    PubMed     Text format     Abstract available


  26. SHEEN YS, Tan KT, Tse KP, Liao YH, et al
    Genetic Alterations in Primary Melanoma in Taiwan.
    Br J Dermatol. 2019 Aug 13. doi: 10.1111/bjd.18425.
    PubMed     Text format     Abstract available


  27. FEARFIELD L, Nobbs J, Petruckevitch A, Harland C, et al
    Severe vitamin D deficiency associated with BRAF mutated melanoma.
    Br J Dermatol. 2019 Aug 5. doi: 10.1111/bjd.18413.
    PubMed     Text format     Abstract available


  28. VUONG K, Armstrong BK, Drummond M, Hopper JL, et al
    Development and external validation study of a melanoma risk prediction model incorporating clinically-assessed naevi and solar lentigines.
    Br J Dermatol. 2019 Aug 4. doi: 10.1111/bjd.18411.
    PubMed     Text format     Abstract available


    July 2019
  29. GAMBICHLER T, Schroter U, Hoxtermann S, Susok L, et al
    Decline of PD-1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade.
    Br J Dermatol. 2019 Jul 30. doi: 10.1111/bjd.18379.
    PubMed     Text format     Abstract available


  30. RIBERO S
    Synergy between MC1R mutations and a high naevus count in increasing melanoma risk in the general population.
    Br J Dermatol. 2019 Jul 28. doi: 10.1111/bjd.18301.
    PubMed     Text format    


  31. GAMBICHLER T, Susok L, Fels M, Schneider-Gold C, et al
    Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female melanoma patient.
    Br J Dermatol. 2019 Jul 19. doi: 10.1111/bjd.18358.
    PubMed     Text format     Abstract available


  32. OLSEN CM
    Reproductive factors and risk of melanoma: still unresolved.
    Br J Dermatol. 2019 Jul 9. doi: 10.1111/bjd.18136.
    PubMed     Text format    


  33. ARMSTRONG J
    Bioenergetic cellular index: a clinical biomarker to identify metabolic adaption in melanoma?
    Br J Dermatol. 2019;181:15-16.
    PubMed     Text format    


  34. FRANKE V
    Talimogene laherparepvec monotherapy, an elegant alternative to systemic immunotherapy for the treatment of early metastatic melanoma.
    Br J Dermatol. 2019;181:20-21.
    PubMed     Text format    


  35. TOLAND AE
    POT1 pathogenic variants: not all telomere pathway genes are equal in risk of hereditary cutaneous melanoma.
    Br J Dermatol. 2019;181:14-15.
    PubMed     Text format    


    June 2019
  36. KIM HS, Kim HJ, Hong ES, Kim KB, et al
    The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea.
    Br J Dermatol. 2019 Jun 24. doi: 10.1111/bjd.18247.
    PubMed     Text format     Abstract available


  37. LIYANAGE UE, Law MH, Barrett JH, Iles MM, et al
    Is there a causal relationship between vitamin D and melanoma risk? : A Mendelian randomization study.
    Br J Dermatol. 2019 Jun 19. doi: 10.1111/bjd.18238.
    PubMed     Text format     Abstract available


  38. MCINERNEY-LEO AM, Finnane A
    The personal touch: does the communication method affect response to melanoma genetic risk?
    Br J Dermatol. 2019;180:1288-1289.
    PubMed     Text format    


    May 2019
  39. CALBET-LLOPART N, Potrony M, Tell-Marti G, Carrera C, et al
    Detection of cell-free circulating BRAF(V) (600E) by droplet digital PCR in melanoma and non-melanoma patients under dermatological surveillance.
    Br J Dermatol. 2019 May 18. doi: 10.1111/bjd.18147.
    PubMed     Text format     Abstract available


  40. RUSSELL-JONES R
    A Brighter Future for Melanoma.
    Br J Dermatol. 2019 May 11. doi: 10.1111/bjd.18122.
    PubMed     Text format     Abstract available


  41. KIM TH, Kim HJ, Seo JW, Song KH, et al
    Efficacy and clinical significance of omitting blue dye injection during sentinel lymph node biopsy before Mohs micrographic surgery for malignant melanoma of the lower extremities.
    Br J Dermatol. 2019 May 11. doi: 10.1111/bjd.18121.
    PubMed     Text format     Abstract available


  42. ELLIS R, Tang D, Nasr B, Greenwood A, et al
    Epidermal AMBRA1 and Loricrin; a paradigm shift in the prognostication and stratification of AJCC stage I melanomas.
    Br J Dermatol. 2019 May 6. doi: 10.1111/bjd.18086.
    PubMed     Text format     Abstract available


  43. VENTURA A, Pitocco R, Di Stefani A, Cota C, et al
    Image Gallery: Peculiar subungual localization of a second primary melanoma during BRAF inhibitors treatment for metastatic melanoma: case report.
    Br J Dermatol. 2019;180:e142.
    PubMed     Text format    


    April 2019
  44. ELEN-LIRA F, Podlipnik S, Potrony M, Tell-Marti G, et al
    Inherited MC1R variants in melanoma patients are associated with better survival in females.
    Br J Dermatol. 2019 Apr 23. doi: 10.1111/bjd.18024.
    PubMed     Text format     Abstract available


  45. GASPARINI G, Madjlessi N, Delyon J, Carmisciano L, et al
    Usefulness of the "two-step method" of digital follow-up in early stage melanoma detection in at high risk French patients - A retrospective 4-year study.
    Br J Dermatol. 2019 Apr 12. doi: 10.1111/bjd.18006.
    PubMed     Text format     Abstract available


  46. DIENG M, Morton RL, Costa DSJ, Butow PN, et al
    Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomised controlled trial.
    Br J Dermatol. 2019 Apr 9. doi: 10.1111/bjd.17990.
    PubMed     Text format     Abstract available


    March 2019
  47. ELIAS ML, Lambert WC
    Surgical Management of Localized Melanoma: A National Cancer Database Retrospective Review.
    Br J Dermatol. 2019 Mar 25. doi: 10.1111/bjd.17901.
    PubMed     Text format     Abstract available


  48. DUFFY DL, Lee KJ, Jagirdar K, Pflugfelder A, et al
    High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk.
    Br J Dermatol. 2019 Mar 1. doi: 10.1111/bjd.17833.
    PubMed     Text format     Abstract available


    February 2019
  49. RESSLER J, Silmbrod R, Stepan A, Tuchmann F, et al
    T-VEC in advanced Melanoma - Complete response in a heart and kidney transplant patient: A case report.
    Br J Dermatol. 2019 Feb 18. doi: 10.1111/bjd.17783.
    PubMed     Text format     Abstract available


  50. STOER NC, Botteri E, Ghiasvand R, Busund M, et al
    Reproductive factors and risk of melanoma: a population-based cohort study.
    Br J Dermatol. 2019 Feb 12. doi: 10.1111/bjd.17771.
    PubMed     Text format     Abstract available


  51. HALK AB, Potjer TP, Kukutsch NA, Vasen HFA, et al
    Surveillance for familial melanoma: recommendations from a national centre of expertise.
    Br J Dermatol. 2019 Feb 11. doi: 10.1111/bjd.17767.
    PubMed     Text format     Abstract available


  52. ZOUTENDIJK J, Tio D, Koljenovic S, van den Bos RR, et al
    Nine percent of biopsy proven lentigo maligna are reclassified as lentigo maligna melanoma after surgery.
    Br J Dermatol. 2019 Feb 4. doi: 10.1111/bjd.17714.
    PubMed     Text format     Abstract available


  53. CHAN MP
    Refining the ever-evolving molecular landscape of spitzoid melanocytic neoplasms.
    Br J Dermatol. 2019;180:262.
    PubMed     Text format    


    January 2019
  54. JIYAD Z, Akhras V
    Incidence of melanoma and outcomes of longitudinal melanonychia in a cohort of cases referred to a London dermatology department.
    Br J Dermatol. 2019 Jan 4. doi: 10.1111/bjd.17607.
    PubMed     Text format     Abstract available


  55. SCHILLING B, Wiesner T
    Tackling melanoma by adjuvant therapy: why, whom and how?
    Br J Dermatol. 2019;180:1-2.
    PubMed     Text format    


  56. VAN AKKOOI ACJ, Hayes A
    Recent developments in lymph node surgery for melanoma.
    Br J Dermatol. 2019;180:5-7.
    PubMed     Text format    


  57. UZUNCAKMAK TK, Akay BN, Ozkanli S
    Different dermoscopic features of clonal seborrhoeic keratoses.
    Br J Dermatol. 2019;180:197-198.
    PubMed     Text format    


    December 2018
  58. MIURA K, Olsen CM, Rea S, Marsden J, et al
    Do airline pilots and cabin crew have raised risks of melanoma and other skin cancers? Systematic review and meta-analysis.
    Br J Dermatol. 2018 Dec 26. doi: 10.1111/bjd.17586.
    PubMed     Text format     Abstract available


  59. FENTON GL, Smit AK, Keogh L, Cust AE, et al
    Exploring the Emotional and Behavioural Reactions to Receiving Personalised Melanoma Genomic Risk Information: A Qualitative Study.
    Br J Dermatol. 2018 Dec 22. doi: 10.1111/bjd.17582.
    PubMed     Text format     Abstract available


  60. NAJERA L, Alonso-Juarranz M, Garrido M, Ballestin C, et al
    Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma.
    Br J Dermatol. 2018 Dec 7. doi: 10.1111/bjd.17513.
    PubMed     Text format     Abstract available


  61. FOX JA, Langbecker D, Rosenberg J, Ekberg S, et al
    Uncertain diagnosis and prognosis in advanced melanoma: A qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies.
    Br J Dermatol. 2018 Dec 4. doi: 10.1111/bjd.17511.
    PubMed     Text format     Abstract available


    November 2018
  62. CORRIE PG, Terheyden P, Ten Tije AJ, Herbst R, et al
    A prospective, observational safety study of patients with BRAF(V) (600) -mutated unresectable or metastatic melanoma treated with vemurafenib [Zelboraf Safety Study (ZeSS)].
    Br J Dermatol. 2018 Nov 29. doi: 10.1111/bjd.17465.
    PubMed     Text format     Abstract available


  63. POTRONY M, Puig-Butille JA, Ribera-Sola M, Iyer V, et al
    POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
    Br J Dermatol. 2018 Nov 19. doi: 10.1111/bjd.17443.
    PubMed     Text format     Abstract available


  64. MAEDA T, Yoshino K, Nagai K, Oaku S, et al
    Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients.
    Br J Dermatol. 2018 Nov 17. doi: 10.1111/bjd.17434.
    PubMed     Text format     Abstract available


  65. OKIYAMA N, Inoue S, Saito A, Nakamura Y, et al
    Antihelix/helix violaceous macules in Japanese patients with anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis.
    Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17431.
    PubMed     Text format     Abstract available


  66. VERAITCH O, Lewis F, Craythorne E, Calonje E, et al
    Management of vulval melanoma in situ with imiquimod.
    Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17433.
    PubMed     Text format     Abstract available


    October 2018
  67. VERYKIOU S, Alexander M, Edwards N, Plummer R, et al
    Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma.
    Br J Dermatol. 2018 Oct 19. doi: 10.1111/bjd.17333.
    PubMed     Text format     Abstract available


    September 2018
  68. KOREKAWA A, Akasaka E, Rokunohe D, Fukui T, et al
    Nagashima-type palmoplantar keratoderma and malignant melanoma in Japanese patients.
    Br J Dermatol. 2018 Sep 26. doi: 10.1111/bjd.17251.
    PubMed     Text format     Abstract available


  69. ROGIERS A, Thomas D, Vander Borght S, van den Oord JJ, et al
    Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Br J Dermatol. 2018 Sep 24. doi: 10.1111/bjd.17250.
    PubMed     Text format     Abstract available


  70. XU S, Stump TK, Jain J, Alshurafa N, et al
    Variation in daily ultraviolet light exposure and sun protection behaviours of melanoma survivors: an observational single-arm pilot study with a wearable sensor.
    Br J Dermatol. 2018 Sep 12. doi: 10.1111/bjd.17196.
    PubMed     Text format     Abstract available


  71. BRANCACCIO G, Napolitano S, Troiani T, Franco R, et al
    Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC?
    Br J Dermatol. 2018 Sep 5. doi: 10.1111/bjd.17145.
    PubMed     Text format     Abstract available


  72. MATTHEWS NH, Risica PM, Ferris LK, Beatson M, et al
    Psychosocial impact of skin biopsies in the setting of melanoma screening - A cross-sectional survey.
    Br J Dermatol. 2018 Sep 5. doi: 10.1111/bjd.17134.
    PubMed     Text format     Abstract available


    August 2018
  73. FOGARTY GB, McLaren KR, Moutrie Z, Poon TSC, et al
    Locally advanced skin cancers of the frail and elderly - consider adaptive split course radiotherapy (ASCRT).
    Br J Dermatol. 2018 Aug 16. doi: 10.1111/bjd.17037.
    PubMed     Text format     Abstract available


  74. CUST AE, Aitken J, Baade P, Whiteman D, et al
    Why a randomised melanoma screening trial may be a good idea.
    Br J Dermatol. 2018 Aug 13. doi: 10.1111/bjd.17089.
    PubMed     Text format     Abstract available


  75. VAN DOORN R
    Methylation marks melanoma metastasis.
    Br J Dermatol. 2018;179:250-251.
    PubMed     Text format    


    June 2018
  76. KEOHANE SG, Proby CM, Newlands C, Motley RJ, et al
    The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, United Kingdom.
    Br J Dermatol. 2018 Jun 19. doi: 10.1111/bjd.16892.
    PubMed     Text format     Abstract available


  77. FARAH M, Nagarajan P, Curry JL, Tang Z, et al
    Spitzoid melanoma with histopathologic features of ALK gene rearrangement exhibiting ALK copy number gain: A novel mechanism of ALK activation in spitzoid neoplasia.
    Br J Dermatol. 2018 Jun 13. doi: 10.1111/bjd.16881.
    PubMed     Text format     Abstract available


  78. HALVORSEN JA, Loberg M, Gjersvik P, Roscher I, et al
    Why a randomized melanoma screening trial is not a good idea.
    Br J Dermatol. 2018 Jun 12. doi: 10.1111/bjd.16784.
    PubMed     Text format    


  79. PODLIPNIK S, Moreno-Ramirez D, Carrera C, Barreiro A, et al
    Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with AJCC stage IIB, IIC and III malignant melanoma.
    Br J Dermatol. 2018 Jun 7. doi: 10.1111/bjd.16833.
    PubMed     Text format     Abstract available


  80. STENEHJEM JS, Veierod MB, Nilsen LT, Ghiasvand R, et al
    Anthropometric factors and Breslow thickness: Prospective data on 2570 cutaneous melanoma cases in the population-based Janus Cohort.
    Br J Dermatol. 2018 Jun 1. doi: 10.1111/bjd.16825.
    PubMed     Text format     Abstract available


    May 2018
  81. WAN MT, Ming ME
    Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal.
    Br J Dermatol. 2018 May 15. doi: 10.1111/bjd.16785.
    PubMed     Text format     Abstract available


  82. CAYUELA A, Cayuela L, Rodriguez-Dominguez S, Lorente AI, et al
    Is melanoma mortality declining in Spain? Analysis of trends 1975-2016.
    Br J Dermatol. 2018 May 14. doi: 10.1111/bjd.16777.
    PubMed     Text format     Abstract available


  83. FUJISAWA Y
    Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors.
    Br J Dermatol. 2018 May 7. doi: 10.1111/bjd.16689.
    PubMed     Text format    


  84. KRAEMER KH, Tamura D, Khan SG
    Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers.
    Br J Dermatol. 2018;178:1009.
    PubMed     Text format    


    April 2018
  85. RAUWERDINK DJW, Roach REJ, Etty M, Kukutsch NA, et al
    Melanoma diagnosis during periodic surveillance of patients with multiple atypical naevi.
    Br J Dermatol. 2018 Apr 28. doi: 10.1111/bjd.16708.
    PubMed     Text format     Abstract available


  86. BAN L, Labbouz S, Grindlay D, Batchelor J, et al
    Risk of skin cancer in people with vitiligo: a systematic review and meta-analysis.
    Br J Dermatol. 2018 Apr 28. doi: 10.1111/bjd.16703.
    PubMed     Text format     Abstract available


  87. LANGAN EA, Gratz V, Billmann F, Zillikens D, et al
    Does the gastrointestinal microbiome contribute to the "obesity paradox" in melanoma survival?
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16681.
    PubMed     Text format     Abstract available


  88. KIM J, Kim YH, Park B, Seo HM, et al
    Multispectral ex vivo photoacoustic imaging of cutaneous melanoma for better selection of the excision margin.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16677.
    PubMed     Text format     Abstract available


  89. MACHET L, Zaragoza J, Finon A, Garnier M, et al
    Baseline neutrophil to lymphocyte ratio in patients with advanced melanoma treated with immune check point inhibitors.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16675.
    PubMed     Text format     Abstract available


  90. HAAS L, Wiesner T, Obenauf AC
    A new era of proactive melanoma therapy: hit hard, hit early.
    Br J Dermatol. 2018;178:817-820.
    PubMed     Text format    


    March 2018
  91. VU M, Adler NR, Wee E, Wolfe R, et al
    Impact of naevus association on survival for nodular and superficial spreading melanomas.
    Br J Dermatol. 2018 Mar 24. doi: 10.1111/bjd.16556.
    PubMed     Text format     Abstract available


  92. FORSCHNER A, Keim U, Hofmann M, Spankuch I, et al
    Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: Results of a prospective multicentre clinical study in 476 pigmented lesions.
    Br J Dermatol. 2018 Mar 22. doi: 10.1111/bjd.16565.
    PubMed     Text format     Abstract available


  93. MARCHAND A, Tallet A, Collin C, Cormier B, et al
    A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Br J Dermatol. 2018 Mar 1. doi: 10.1111/bjd.16499.
    PubMed     Text format     Abstract available


  94. BARRAGAN-ESTUDILLO ZF, Jesus-Silva MA, Chavez-Bourgeois MM, Brito J, et al
    Image Gallery: Transition pattern in acral melanoma.
    Br J Dermatol. 2018;178:e225.
    PubMed     Text format    


    February 2018
  95. LONGO C, Lallas A, Kyrgidis A, Bassoli S, et al
    Wide skin markings pattern - melanoma descriptor or patient-related factor?: reply from authors.
    Br J Dermatol. 2018 Feb 7. doi: 10.1111/bjd.16430.
    PubMed     Text format     Abstract available


  96. RISHPON A, Marchetti M, Marghoob A
    Wide skin markings pattern - melanoma descriptor or patient-related factor?
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16420.
    PubMed     Text format     Abstract available


  97. FUJISAWA Y, Yoshino K, Otsuka A, Funakoshi T, et al
    Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16427.
    PubMed     Text format     Abstract available


  98. DANDO EE, Lim GFS, Ho J, James A, et al
    Image Gallery: Pigmented mammary Paget disease: a rare clinicopathological variant mimicking melanoma.
    Br J Dermatol. 2018;178:e143.
    PubMed     Text format    


  99. CUST AE
    Prognostic features for acral lentiginous melanoma.
    Br J Dermatol. 2018;178:311-312.
    PubMed     Text format    


  100. BELL KJL, Cust AE
    Beyond country-specific incidence and mortality: the global burden of melanoma.
    Br J Dermatol. 2018;178:315-316.
    PubMed     Text format    


    January 2018
  101. BORSARI S, Pampena R, Benati E, Bombonato C, et al
    In vivo dermoscopic and confocal microscopy multi-step algorithm to detect in situ melanomas.
    Br J Dermatol. 2018 Jan 21. doi: 10.1111/bjd.16364.
    PubMed     Text format     Abstract available


  102. LAINO AM, Berry EG, Jagirdar K, Lee KJ, et al
    Iris pigmented lesions as a marker of cutaneous melanoma risk: an Australian case-control study.
    Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16323.
    PubMed     Text format     Abstract available


  103. VERYKIOU S, Edwards N, Hill D
    How breakthroughs in translational research have impacted treatment strategies for melanoma.
    Br J Dermatol. 2018;178:5-8.
    PubMed     Text format    


  104. MUTHIAH S, Tang D, Nasr B, Verykiou S, et al
    A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma.
    Br J Dermatol. 2018;178:1-4.
    PubMed     Text format    


  105. WIESNER T, Zbyszewski A
    Progress in the diagnosis and therapy of melanoma.
    Br J Dermatol. 2018;178:12-14.
    PubMed     Text format    


  106. WEHNER MR
    Sunscreen and melanoma prevention: evidence and expectations.
    Br J Dermatol. 2018;178:15-16.
    PubMed     Text format    


  107. HWANG SJE, Fernandez-Penas P
    Pigmentary evolution with pembrolizumab use.
    Br J Dermatol. 2018;178:32-33.
    PubMed     Text format    


    December 2017
  108. MCINERNEY-LEO AM, Wheeler L, Sturm RA, Tan JM, et al
    Point mutation in p14(ARF) -specific exon 1beta of CDKN2A causing familial melanoma and astrocytoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16275.
    PubMed     Text format     Abstract available


  109. DE UNAMUNO BUSTOS B, Murria Estal R, Perez Simo G, Simarro Farinos J, et al
    Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16254.
    PubMed     Text format     Abstract available


  110. SALOMON G, Maza A, Boulinguez S, Paul C, et al
    Efficacy of anti-PD-1 on skin carcinomas and melanoma metastases in an Xeroderma Pigmentosum patient.
    Br J Dermatol. 2017 Dec 23. doi: 10.1111/bjd.16270.
    PubMed     Text format     Abstract available


  111. OLSEN CM, Wilson LF, Green AC, Biswas N, et al
    How many melanomas might be prevented if more people applied sunscreen regularly?
    Br J Dermatol. 2017 Dec 14. doi: 10.1111/bjd.16079.
    PubMed     Text format     Abstract available


    November 2017
  112. WINSLOW UC, Nordestgaard BG, Afzal S
    High plasma 25-hydroxyvitamin D and high risk of non-melanoma skin cancer: a Mendelian randomisation study of 97849 individuals.
    Br J Dermatol. 2017 Nov 16. doi: 10.1111/bjd.16127.
    PubMed     Text format     Abstract available


  113. DEL PUERTO C, Navarrete-Dechent C, Molgo M, Camargo CA Jr, et al
    Immunohistochemical expression of vitamin D receptor in melanocytic nevi and cutaneous melanoma. A case-control study.
    Br J Dermatol. 2017 Nov 6. doi: 10.1111/bjd.16103.
    PubMed     Text format     Abstract available


    October 2017
  114. TRAN AD, Fogarty G, Nowak AK, Espinoza D, et al
    A systematic review and meta-analysis of utility estimates in melanoma.
    Br J Dermatol. 2017 Oct 27. doi: 10.1111/bjd.16098.
    PubMed     Text format     Abstract available


  115. SEO JW, Ha SM, Song KH
    Insulin-Like Growth Factor-II mRNA-Binding Protein 3 as a Novel Prognostic Biomarker for Acral Lentiginous Melanoma.
    Br J Dermatol. 2017 Oct 19. doi: 10.1111/bjd.16077.
    PubMed     Text format     Abstract available


  116. BASSOLI S, Kyrgidis A, Ciardo S, Casari A, et al
    Uncovering the diagnostic dermoscopic features of flat melanomas located on the lower limbs.
    Br J Dermatol. 2017 Oct 7. doi: 10.1111/bjd.16030.
    PubMed     Text format     Abstract available


  117. SCHAIDER H, Sturm RA
    The evolving universe of BRAF mutations in melanoma.
    Br J Dermatol. 2017;177:893.
    PubMed     Text format    


  118. ROBINSON JK, Spring B
    Personalized melanoma genomic risk information:perception of shared risk initiates sharing with family.
    Br J Dermatol. 2017;177:890-891.
    PubMed     Text format    


    September 2017
  119. SATTLER EC, Ertl-Wagner B, Pellegrini C, Peris K, et al
    Cutaneous melanoma in Birt-Hogg-Dube syndrome - part of the clinical spectrum?
    Br J Dermatol. 2017 Sep 4. doi: 10.1111/bjd.15937.
    PubMed     Text format     Abstract available


  120. ZNAOR A
    Melanoma burden, healthcare utilization and the potential for overdiagnosis in the elderly U.S. population.
    Br J Dermatol. 2017;177:625.
    PubMed     Text format    


    August 2017
  121. YOULDEN DR, Baade PD, Aitken JF, Green AC, et al
    Prognostic importance of a second invasive primary melanoma according to tumor stage.
    Br J Dermatol. 2017 Aug 3. doi: 10.1111/bjd.15863.
    PubMed     Text format     Abstract available


  122. BERK-KRAUSS J, Stein JA
    The role of access to care in acral lentiginous melanoma survival.
    Br J Dermatol. 2017;177:341-342.
    PubMed     Text format    


  123. HILL D, Lovat P
    Cover Image: Invasion of a cutaneous melanoma tumour.
    Br J Dermatol. 2017;177:599.
    PubMed     Text format    


    July 2017
  124. ADLER NR, Kelly JW, Haydon A, McLean CA, et al
    Clinicopathological characteristics and prognosis of patients with multiple primary melanomas.
    Br J Dermatol. 2017 Jul 28. doi: 10.1111/bjd.15855.
    PubMed     Text format     Abstract available


  125. DIAS-SANTAGATA D, Selim MA, Su Y, Peng Y, et al
    KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.
    Br J Dermatol. 2017 Jul 22. doi: 10.1111/bjd.15836.
    PubMed     Text format     Abstract available


  126. TERAMOTO Y, Keim U, Gesierich A, Schuler G, et al
    Acral lentiginous melanoma - a skin cancer with unfavourable prognostic features. A study of the German Central Malignant Melanoma Registry (CMMR) in 2050 patients.
    Br J Dermatol. 2017 Jul 14. doi: 10.1111/bjd.15803.
    PubMed     Text format     Abstract available


  127. GIBBS DC, Ward SV, Orlow I, Cadby G, et al
    Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.
    Br J Dermatol. 2017 Jul 1. doi: 10.1111/bjd.15784.
    PubMed     Text format     Abstract available


  128. MAHER NG, Guitera P
    Imiquimod treatment for lentigo maligna: LIMIT-1 trial.
    Br J Dermatol. 2017;177:324-325.
    PubMed     Text format    


    June 2017
  129. SMIT AK, Keogh LA, Newson AJ, Butow PN, et al
    Does personalised melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?
    Br J Dermatol. 2017 Jun 19. doi: 10.1111/bjd.15744.
    PubMed     Text format     Abstract available


  130. KIM SK, Barker CA
    Outcomes of radiation therapy for advanced T3/T4 non-melanoma cutaneous squamous cell and basal cell carcinoma.
    Br J Dermatol. 2017 Jun 15. doi: 10.1111/bjd.15728.
    PubMed     Text format     Abstract available


  131. CERIO R, Moir G
    Palliative electrochemotherapy treatment of metastatic malignant melanoma.
    Br J Dermatol. 2017;176:1427.
    PubMed     Text format    


  132. JONES G
    Methotrexate increases the risk of melanoma: or does it?
    Br J Dermatol. 2017;176:1429-1430.
    PubMed     Text format    


    May 2017
  133. RIBERO S, Carrera C, Tell-Marti G, Pastorino C, et al
    Amelanotic melanoma in oculocutaneous albinism: a genetic, dermoscopic and reflectance confocal microscopy study.
    Br J Dermatol. 2017 May 27. doi: 10.1111/bjd.15687.
    PubMed     Text format     Abstract available


  134. SWETTER SM
    Challenges of treating melanoma in situ, lentigo maligna type: is pathological clearance the gold standard?
    Br J Dermatol. 2017;176:1115-1116.
    PubMed     Text format    


  135. ELLIS RA
    T-type calcium channels as potential biomarkers in melanoma.
    Br J Dermatol. 2017;176:1122.
    PubMed     Text format    


  136. KRENGEL S, Reyes-Mugica M
    Melanoma risk in congenital melanocytic naevi.
    Br J Dermatol. 2017;176:1114.
    PubMed     Text format    


    April 2017
  137. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease: reply from authors.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15626.
    PubMed     Text format     Abstract available


  138. SALEH DB
    RE: Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15619.
    PubMed     Text format     Abstract available


  139. ASGARI MM, Shen L, Sokil MM, Yeh I, et al
    Prognostics factors and survival in acral lentiginous melanoma.
    Br J Dermatol. 2017 Apr 22. doi: 10.1111/bjd.15600.
    PubMed     Text format     Abstract available


  140. ROCHA L, Menzies SW, Lo S, Avramidis M, et al
    Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions.
    Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15595.
    PubMed     Text format     Abstract available


  141. GUALANO MR, Osella-Abate S, Scaioli G, Marra E, et al
    Prognostic role of Histologic regression in primary cutaneous melanoma: A Systematic Review and Meta-analysis.
    Br J Dermatol. 2017 Apr 7. doi: 10.1111/bjd.15552.
    PubMed     Text format     Abstract available


  142. NIJSTEN T, Wakkee M
    The four Ws of skin cancer surveillance in patients with melanoma: Why? Who? When? Where?
    Br J Dermatol. 2017;176:839-841.
    PubMed     Text format    


  143. MONTAUDIE H, Pradelli J, Passeron T, Lacour JP, et al
    Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Br J Dermatol. 2017;176:1060-1063.
    PubMed     Text format     Abstract available


    March 2017
  144. LOTT JP, Wang Q, Titus LJ, Onega T, et al
    Temporal Trends in Healthcare Utilization following Primary Melanoma Diagnosis among Medicare Beneficiaries.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15530.
    PubMed     Text format     Abstract available


  145. KARIMKHANI C, Green AC, Nijsten T, Weinstock MA, et al
    The Global Burden of Melanoma: Results from Global Burden of Disease Study 2015.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15510.
    PubMed     Text format     Abstract available


  146. KOGUCHI-YOSHIOKA H, Okiyama N, Iwamoto K, Matsumura Y, et al
    Intravenous immunoglobulin contributes to control anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis with palmar violaceous macules/papules.
    Br J Dermatol. 2017 Mar 27. doi: 10.1111/bjd.15499.
    PubMed     Text format     Abstract available


  147. LICCIARDELLO M, T Giura M, Rozzo G, Marra E, et al
    Arrhythmias in metastatic melanoma patient treated with targeted therapy and ICD implant.
    Br J Dermatol. 2017 Mar 10. doi: 10.1111/bjd.15447.
    PubMed     Text format     Abstract available


  148. RICHTIG G, Hoeller C, Kashofer K, Aigelsreiter A, et al
    Beyond the BRAFV600E hotspot - Biology and clinical implications of rare BRAF gene mutations in melanoma patients.
    Br J Dermatol. 2017 Mar 9. doi: 10.1111/bjd.15436.
    PubMed     Text format     Abstract available


    February 2017
  149. CORR M, Roulston G, King N, Dornan T, et al
    Living with 'melanoma'...for a day: a phenomenological analysis of medical students' simulated experiences.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15402.
    PubMed     Text format     Abstract available


  150. TSAI S, Scott JF, Keller JJ, Gerstenblith MR, et al
    Cutaneous malignancies identified on an inpatient Dermatology consult service.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15401.
    PubMed     Text format     Abstract available


  151. JORDAN M, Ghoreschi K
    Anti-melanoma differentiation-associated protein 5 autoantibodies as a marker for dermatomyositis-associated interstitial lung disease.
    Br J Dermatol. 2017;176:294-295.
    PubMed     Text format    


    January 2017
  152. WOLNER ZJ, Marghoob AA, Pulitzer MP, Postow MA, et al
    A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
    Br J Dermatol. 2017 Jan 28. doi: 10.1111/bjd.15354.
    PubMed     Text format     Abstract available


  153. VANHAECKE C, Deilhes F, Chanal J, Regnier-Rosencher E, et al
    BRAFV600 inhibitor discontinuation after complete response in advanced melanoma. A retrospective analysis of 16 patients.
    Br J Dermatol. 2017 Jan 27. doi: 10.1111/bjd.15345.
    PubMed     Text format     Abstract available


  154. KUNTE C, Letule V, Gehl J, Dahlstroem K, et al
    Electrochemotherapy in the treatment of metastatic malignant melanoma: A prospective cohort study by InspECT.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15340.
    PubMed     Text format     Abstract available


  155. MINAGAWA A, Omodaka T, Koga H, Yokokawa Y, et al
    Nail apparatus melanoma thickness is associated with side and age.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15318.
    PubMed     Text format     Abstract available


  156. KINSLER VA, O'Hare P, Bulstrode N, Calonje JE, et al
    Melanoma in congenital melanocytic naevi.
    Br J Dermatol. 2017 Jan 12. doi: 10.1111/bjd.15301.
    PubMed     Text format     Abstract available


    December 2016
  157. NEITTAANMAKI N, Salmivuori M, Polonen I, Jeskanen L, et al
    Hyperspectral imaging in detecting dermal invasion in lentigo maligna melanoma.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15267.
    PubMed     Text format     Abstract available


  158. USHER-SMITH JA, Kassianos AP, Emery JD, Abel GA, et al
    Identifying people at higher risk of melanoma across the U.K.: a primary-care-based electronic survey.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15181.
    PubMed     Text format     Abstract available


  159. HERMS F, Franck N, Kramkimel N, Fichel F, et al
    Neutrophilic eccrine hidradenitis in 2 patients treated with BRAF inhibitors: a new cutaneous adverse event.
    Br J Dermatol. 2016 Dec 22. doi: 10.1111/bjd.15259.
    PubMed     Text format     Abstract available


  160. RICHTIG G, Richtig E, Kashofer K, Koch L, et al
    Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15222.
    PubMed     Text format     Abstract available


  161. LINOS E, Li WQ, Han J, Li T, et al
    Lifetime UV exposure and Lentigo Maligna Melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15218.
    PubMed     Text format     Abstract available


  162. SPENDER LC, Inman GJ
    Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma.
    Br J Dermatol. 2016;175:1140-1141.
    PubMed     Text format    


  163. YELAMOS O, Nehal KS
    Integrating clinical information, dermoscopy and reflectance confocal microscopy to improve the diagnostic accuracy and confidence of amelanotic and lightly pigmented melanomas.
    Br J Dermatol. 2016;175:1147-1148.
    PubMed     Text format    


  164. HAASS NK
    JNK-ERK signalling in melanoma: rewired or entangled?
    Br J Dermatol. 2016;175:1139-1140.
    PubMed     Text format    


  165. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2016;175:1340-1341.
    PubMed     Text format    


    November 2016
  166. SPEIGL L, Janssen N, Weide B, Pawelec G, et al
    Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.
    Br J Dermatol. 2016 Nov 21. doi: 10.1111/bjd.15194.
    PubMed     Text format     Abstract available


  167. MAHER NG, Blumetti TP, Gomes EE, Cheng HM, et al
    Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions.
    Br J Dermatol. 2016 Nov 18. doi: 10.1111/bjd.15187.
    PubMed     Text format     Abstract available


  168. POLESIE S, Gillstedt M, Sonnergren HH, Osmancevic A, et al
    Methotrexate Treatment and Risk for Cutaneous Malignant Melanoma - a Retrospective Comparative Registry-based Cohort Study.
    Br J Dermatol. 2016 Nov 10. doi: 10.1111/bjd.15170.
    PubMed     Text format     Abstract available


  169. BARRETT JH
    Telomere length and melanoma - is there a straightforward relationship?
    Br J Dermatol. 2016;175:865-866.
    PubMed     Text format    


  170. ELLIKER KR, Williams HC
    Detection of skin cancer odours using dogs: a step forward in melanoma detection training and research methodologies.
    Br J Dermatol. 2016;175:851-852.
    PubMed     Text format    


  171. EISEMANN N
    Routine health data in skin cancer screening evaluation.
    Br J Dermatol. 2016;175:862.
    PubMed     Text format    


    October 2016
  172. RICHTIG G, Byrom L, Kupsa R, Schaider H, et al
    Pregnancy as driver for melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15124.
    PubMed     Text format     Abstract available


  173. MAIQUES O, Macia A, Moreno S, Barcelo C, et al
    Immunohistochemical analysis of T-type calcium channels in acquired melanocytic nevi and melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15121.
    PubMed     Text format     Abstract available


  174. O'SHEA SJ, Davies JR, Newton-Bishop JA
    Vitamin D, vitamin A, the primary melanoma transcriptome and survival.
    Br J Dermatol. 2016;175 Suppl 2:30-34.
    PubMed     Text format     Abstract available


    September 2016
  175. PIZZICHETTA MA, Kittler H, Stanganelli I, Ghigliotti G, et al
    Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma.
    Br J Dermatol. 2016 Sep 28. doi: 10.1111/bjd.15093.
    PubMed     Text format     Abstract available


  176. WEINSTOCK MA, Lott JP, Wang Q, Titus LJ, et al
    Skin Biopsy Utilization and Melanoma Incidence among Medicare Beneficiaries.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15077.
    PubMed     Text format     Abstract available


  177. LO MC, Maraka J, Garioch J, John WG, et al
    Monitoring vitamin D in the melanoma patient - impact of sun avoidance on vitamin D levels of melanoma patients at a tertiary UK referral melanoma service.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15062.
    PubMed     Text format     Abstract available


  178. FOX J
    A changing treatment paradigm: the role of palliative care in metastatic melanoma.
    Br J Dermatol. 2016;175:462-3.
    PubMed     Text format    


    June 2016
  179. WANG CC, Tang CH, Wang CY, Huang SY, et al
    Risk of skin cancer in chronic haemodialysis patients: a nationwide, population-based study in Taiwan.
    Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14789.
    PubMed     Text format     Abstract available


    May 2016
  180. GUITERA P, Menzies SW, Argenziano G, Longo C, et al
    Dermoscopy and in vivo confocal microscopy are complimentary techniques for the diagnosis of difficult amelanotic and light colored skin lesions.
    Br J Dermatol. 2016 May 13. doi: 10.1111/bjd.14749.
    PubMed     Text format     Abstract available


  181. LLOYD-LAVERY A, Hodgson T, Coupe N, Bond S, et al
    Delayed oral toxicity from long-term vemurafenib therapy.
    Br J Dermatol. 2016;174:1159-60.
    PubMed     Text format    


  182. LALLAS A, Tschandl P, Kyrgidis A, Stolz W, et al
    Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis.
    Br J Dermatol. 2016;174:1079-85.
    PubMed     Text format     Abstract available


  183. GREVELING K, de Vries K, van Doorn MB, Prens EP, et al
    A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose.
    Br J Dermatol. 2016;174:1134-6.
    PubMed     Text format    


    April 2016
  184. NILSEN LT, Hannevik M, Veierod MB
    Ultraviolet exposure from indoor tanning devices: a systematic review.
    Br J Dermatol. 2016;174:730-40.
    PubMed     Text format     Abstract available


    March 2016
  185. PARTARRIEU-MEJIAS F, Perez-Velasquez F
    Image Gallery: Xeroderma pigmentosum.
    Br J Dermatol. 2016;174:e12.
    PubMed     Text format    


  186. DE VRIES K, Greveling K, Prens LM, Munte K, et al
    Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision.
    Br J Dermatol. 2016;174:588-93.
    PubMed     Text format     Abstract available


  187. BELLON T, Lerma V, Gonzalez-Valle O, Gonzalez Herrada C, et al
    Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
    Br J Dermatol. 2016;174:621-4.
    PubMed     Text format     Abstract available


    February 2016
  188. LEE S, Duffy DL, McClenahan P, Lee KJ, et al
    Heritability of naevus patterns in an adult twin cohort from the Brisbane Twin Registry: a cross-sectional study.
    Br J Dermatol. 2016;174:356-63.
    PubMed     Text format     Abstract available


    January 2016
  189. KAI AC, Richards T, Coleman A, Mallipeddi R, et al
    Five-year recurrence rate of lentigo maligna after treatment with imiquimod.
    Br J Dermatol. 2016;174:165-8.
    PubMed     Text format     Abstract available


    August 2015
  190. CHAVEZ-BOURGEOIS M, Iglesias P, Brito J, Malvehy J, et al
    Skin cancers detected as casual findings with Reflectance Confocal Microscopy (RCM) in the assessment of melasma treatment.
    Br J Dermatol. 2015 Aug 12. doi: 10.1111/bjd.14066.
    PubMed     Text format     Abstract available


    June 2015
  191. BENATI E, Zalaudek I, Piana S, Argenziano G, et al
    In vivo detection of peripheral clefting in melanocytic lesions.
    Br J Dermatol. 2015 Jun 23. doi: 10.1111/bjd.13959.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: